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Chemokines and T Lymphocytes: Review
More than an Attraction
Members of all four families are known to attract vari-
ous subsets of T lymphocytes, and it is by virtue of
their diversity that chemokines are ideal molecules for
Stephen G. Ward,*³ Kevin Bacon,²
and John Westwick*
*Pharmacology Group
mediating a plethora of events such as selective traffick-Department of Pharmacy and Pharmacology
ing of T lymphocyte subsets from intravascular to extra-Bath University
vascular compartments, trafficking within lymph nodeClaverton Down
and thymus, and/or recirculation from tissues to lym-Bath, BA2 7AY
phatics. However, the large number of chemokines andUnited Kingdom
their receptors, together with the expression of chemo-²Neurocrine Biosciences
kine receptors on cells other than leukocytes (such asSan Diego, California 92121
epithelial, endothelial, and smooth muscle cells), is
probably indicative of the importance of these mole-
cules in a wide range of biological functions. For exam-Not so long ago, most people outside of the field, when
ple, in addition to their role as chemoattractants forasked ªWhat are chemokines?º might have responded,
leukocytes, chemokines play a role in regulating angio-with some apathy, ªAren't they those small proteins in-
genesis. However, this review will focus on the currentvolved in the recruitment of leukocytes?º Well, general
understanding of the biochemical and functional role ofawareness and understanding of this field has changed
chemokines and their receptors in T lymphocytebiology.considerably in the past 3 years or so. The term ªchemo-
In this respect, perhaps the most exciting and influentialkineº was adopted in 1992 to describe a family of closely
discovery this decade is the finding that human immuno-related chemotactic cytokines withconserved sequences,
deficiency virus-1 (HIV-1) uses chemokine receptors forknown to be potent attractors for various leukocyte sub-
entry into cells. Although the sole purpose of chemo-sets such as neutrophils, monocytes, or lymphocytes
kines is probably not that of sharing receptors with(Lindley et al., 1993). The history of chemokines can be
HIV-1, it is undeniable that this finding is responsible fortraced back as far as 1977 with the characterization of
considerably raising the scientific profile of chemokinesplatelet factor 4, although the prototypical chemokine
and for unleashing an astounding surge of research intoIL-8 was not described until 1987 (Baggiolini et al., 1997).
this fieldÐso much so that chemokines now attractIdentification of other structurally related chemotactic
almost as many researchers as they do leukocytes.cytokines quickly followed with advances in molecular
Accordingly, there has been rapid progress in under-cloning techniques and availability of bioinformatics-
standing how the expression of chemokines and theirbased analyses of nucleotide databases. During the last
receptors is regulated, what biochemical events are uti-10 years, it has become apparent that chemokines are
lized by the receptors, and the biological role of chemo-a large superfamily consisting of four subfamilies that
kines and chemokine receptors in T lymphocyte biology,display between two and four highly conserved NH2-
with implications that stretch far beyond the role ofterminal cysteine amino acid residues. The CXC (or a)
chemokine receptors as binding sites for AIDS viruses.familiy has the first two NH2-terminal cysteines sepa-
So today, when asked ªWhat are chemokines?º, mostrated by one nonconserved amino acid residue. In con-
people might venture a somewhat more excited andtrast, the CC (or b) family has these cysteines in juxtapo-
informed reply than the one suggested earlier.sition, and the C (or g) family has one lone NH2-terminal
cysteine residue, while the CX3C (or d) family has these
Chemokine Receptor Expression on Restingcysteines separated by three intervening amino acids
and Activated T Lymphocytes(Baggiolini et al., 1997). There are now well over 40 char-
The known chemokine receptors, together with theiracterized chemokines (some of which are listed in Table
respective ligands, are shown in Table 2. Chemokine1 and Table 2) as well as a number of virally encoded
receptors are seven-transmembrane-spanning, pertus-chemokine-like proteins, so this family far outnumbers
sis toxin±sensitive, Gprotein±coupled receptors that areother cytokine families. Most chemokines fall into the
similar to many other seven-transmembrane-spanningCXC and CC groups, since there is only one C and
receptors and have a number of conserved motifs, in-one CX3C chemokine known in human. The discovery cluding the DRYLAIV motif in the second intracellularof chemokine receptors also appears to be a modern
loop domain (Baggiolini et al., 1997). The only exception
growth industry. There are now at least 15 known che-
is the Duffy antigen receptor for chemokines (DARC),
mokine receptors, many of which exhibit multiple ligand
which has less than 20% amino acid identity with CXC
specificity, although the chemokine/ligand promiscuity
and CC chemokine receptors. DARC is the only known
does not usually cross CC versus CXC chemokine
chemokine receptor that can bind both CC and CXC
boundaries (Table 2). In addition, there are several or-
chemokines. In addition, DARC lacks the DRYLAIV motif,
phan and virally encoded chemokine receptors, so the
is not coupled to G proteins, and has not been reported
number of chemokine receptors will likely increase sub-
to elicit any detectable signal transduction events. Given
stantially over the next few years.
the chemotactic effects of chemokines on T lympho-
cytes, it was a natural assumption that T cells should
express chemokine receptors, and there has been in-³To whom correspondence should be addressed (e-mail: prssgw
@bath.ac.uk). tense effort to determine which chemokine receptors
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Chemokine Receptors as MarkersTable 1. Some Common Chemokine Abbreviations
of T Lymphocyte Differentiation
CXC Chemokines The notion that chemokine receptors are expressed on
BCA-1 B cell attracting chemokine-1
T lymphocytes depending on their state of activation orGROa Growth related oncogene-a
differentiation is supported by two recent observations:IL-8 Interleukin 8
(1) expression of CCR4 and CCR3 (and perhaps CCR7)IP-10 Interferon-g inducible protein
MIG Monokine induced by interferon-g has been linked to the program of Th type 2 differentia-
SDF Stromal cell-derived factor tion in vitro (Gerber et al., 1997; Sallusto et al., 1997;
Bonecchi et al., 1998 ); and (2) CXCR3 and CCR5 areCC Chemokines
DC-CK1 Dendritic cell-derived chemokine-1 prefentially expressed on human Th1 cells and are pres-
ELC EBI1-ligand chemokine ent on T lymphocytes recovered from the synovial fluid
LARC Liver and activation-regulated of rheumatoid joints that exhibit a Th1 phenotype, while
chemokine
CXCR4 and CCR2 (and maybe CCR1) are expressedMCP-1 Monocyte chemotactic protein-1
equally on both Th1 and Th2 cells (Bonecchi et al., 1998;MDC Macrophage-derived chemokine
Loetscher et al., 1998; Qin et al., 1998). This pattern ofMIP-1a Macrophage inflammatory protein-1a
SLC Secondary lymphoid tissue chemokine receptor expression correlates with the efficient at-
RANTES Regulated on activation, normal T cell traction of Th1 but not Th2 cells by the appropriate
expressed and secreted CC chemokine ligands MIP-1a, MIP-1b, and RANTES.
TARC Thymus and activation-regulated
Moreover, SDF-1 and MCP-1, which bind to CXCR4 andchemokine
CCR2, respectively, exerted chemotactic effects onTECK Thymus-expressed chemokine
both Th1 and Th2 cells (Siveke and Hamann, 1998).
Chemokine receptor expression and association with
Th1 and Th2 phenotypes can be affected by other cyto-
are expressed on T cells. Accordingly, it is now known kines known to affect T lymphocyte polarization such
that T cells express most of the known CC, CXC, and as a-interferon (promotes Th1 phenotype) and trans-
CX3CR chemokine receptors listed in Table 2. forming growth factor b (promotes Th2 phenotype).
Hence, transforming growth factor b inhibited CCR3 butThe precise pattern of chemokine receptor expression
enhanced CCR4 expression, while a-interferon inhibiteddepends on the activation state of the T cell. For in-
CCR3 but up-regulated CXCR3 expression (Sallusto etstance, expression of a number of chemokine receptors
al., 1998). These observations imply that T cell differenti-such as CCR1, CCR2, CCR5, CXCR4, and CX3CR1 is
ation may well require migratory capacity as well asmarkedly up-regulated after mitogenic stimulation and/
distinct cytokine production patterns. In addition, che-or prolonged treatment of T lymphocytes with IL-2
mokines may be part of effector and amplification mech-(Loetscher et al., 1996b; Carroll et al., 1997). Moreover,
anisms of polarized Th1- and Th2-mediated immunesome receptors such as CXCR3 are restricted to acti-
responses, and their receptors might serve as Th1 ver-vated T cells, and this correlates well with the observa-
sus Th2 markers (Figure 1) as well as targets for selectivetion that its ligands IP-10 and MIG both attract activated
modulation of T cell±dependent immunity. There is cer-T cells (Loetscher et al., 1996a). Indeed, for the most
tainlyevidence that differential expression of chemokinepart, chemokine receptor expression does correlate well
receptors may influence functional T cell responseswith the known chemotactic effects of the respective
other than chemotaxis, as evidenced by the demonstra-ligands on T lymphocyte subsets. For example, CXCR4
tion that CC chemokines (e.g., RANTES, MIP-1a, and(the receptor for SDF-1), is expressed predominantly on
MCP-1) promote lymphocyte activation and/or differen-CD45RA1 naive T lymphocytes (Bleul et al., 1997). This
tiation (Bacon et al., 1995b; Taub et al., 1996).finding is consistent with the view that SDF-1, constitu-
The costimulatory T cell molecule CD28 can regulatetively expressed in a broad range of tissues, is involved
the expression of a number of chemokine receptors (e.g.,in basal trafficking of naive lymphocytes. In contrast,
CCR1, CCR2, and CCR5), which will be discussed inCCR5 is expressed mainly on the CD45RO1 memory
further detail later. It is tempting to speculate, therefore,
subset, which migrates in response to RANTES, the ma-
that the differential expression of chemokine receptors
jor ligand for CCR5 (Bleul et al., 1997). Furthermore,
during T lymphocyte differentiation may be related to
CCR2 expression on the memory T cell subset correlates the differential immune regulation that is exhibited by
with the response of these cells to MCP-1 in chemotaxis the natural ligands for the T cell costimulatory molecule
assays (Qin et al., 1996). Some controversy surrounds CD28, namely, B7.1 and B7.2, which have been demon-
the expression of the two IL-8 receptors CXCR1 and strated to promote Th1 and Th2 differentiation, respec-
CXCR2 on T cells, since they have been reported to be tively (Freeman et al., 1995). In this respect, eotaxin (the
restricted to the NK-like cells within the T cell lineage major ligand for CCR3) deserves a particular mention,
that are recruited by IL-8 (Qin et al., 1996). However, since eotaxin expression is up-regulated in tissues
other groups have clearly demonstrated high affinity known to be sites of allergic reactions, such as the
binding of IL-8 to T cell populations that have not been airways, and is important for the attractionof eosinophils
enriched for NK cells. If there were a restriction of CXCR1 leading to lung eosinophilia (Gonzalo et al., 1996). The
and CXCR2 toNK cells, it is unlikely that thechemotactic generation and maintenance of an allergic reaction re-
responses of CD41 and CD81 T cells to IL-8 would have quires Th2 cells as a source of IL-4 and IL-5, and these
cytokines serve as growth and stimulation factors forbeen detected (Bacon et al., 1995a).
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Table 2. Human Chemokine Receptor Expression and Ligand Specificity
Receptors T Lymphocyte Expressiona Ligand
CXC Chemokines
CXCR1 1 IL-8
CXCR2 1 IL-8, GROa, GroB
CXCR3 1 MIG, IP-10
CXCR4 (LESTR/Fusin) 1 SDF-1a/b
CXCR5 2 BCA-1
CC Chemokines
CCR1 1 MIP-1a,RANTES, MCP-3
MIP-5 (leukotactin-1)
CCR2A/B 1 MCP-1, MCP-2, MCP-3,
MCP-4, MCP-5




CCR5 1 MIP-1a, MIP-1b,RANTES
CCR6 1 MIP-3a (LARC or Exodus)
CCR7 1 MIP-3b (Exodus-3 or ELC),
SLC (Exodus-2)
CCR8 1 I-309, TARC, MIP-1b
D6c ? MIP-1a, MIP-1b, RANTES
(Putatively CCR9 or CCR10) MCP21, 22, 23, 24, Eotaxin
C Chemokines
XCR1 (GPR5)b 1 Lymphotactin
CX3C Chemokine
CX3CR1 (V28) 1 Fractalkine
Miscellaneous
DARC Unknown IL-8, GROa,
RANTES, MCP-1, TARC
a Expression may vary between T cell subsets and/or T cell lines or activation state of the T cells.
b Designation of GPR5 as XCR1 awaits confirmation.
c Sequence of human D6/CCR9 is identical to sequence submitted for human CCR10. Hence, designation of human D6 as CCR9 awaits
confirmation.
The most commonly used names are used for the well-characterized chemokines listed, although some alternative names are indicated in
parentheses for recently identified chemokines. See Table 1 for abbreviations.
basophils and eosinophils. Hence, the presence of also provide a potential target for therapeutic interven-
tion. Given that CD28-dependent costimulation has beenCCR3 on both eosinophils and Th2 cells, as well as the
observation that T cells colocalize with eosinophils in demonstrated to be required for induction of a lung
mucosal Th2 immune response and airway eosinophilia,diseased tissues, may suggest a possible pathogenetic
mechanism for T cell recruitment in the airways and may a close relationship between CD28 and regulation of
CCR3 expression is an interesting possibility (Harris et
al., 1997).
Chemokines and Lymphocyte Development
The importance of chemokines in T lymphocyte recruit-
ment during allergic inflammation is well documented
(Baggiolini et al., 1997). With the discovery and charac-
terization of new chemokines, it is becoming clear that
control of T lymphocyte recruitment by chemokines is
not limited to inflammatory situations. For example, dur-
ing their development and differentiation, lymphocytes
move through different tissue compartments, although
the mechanisms by which this complex cellular traffick-
ing is regulated are not fully understood. However, a
group of recently identified chemokines including TARC,
ELC, SLC, LARC, and DC-CK1 are constitutively ex-
pressed at high levels in the thymus, lymph nodes, and
other lymphoid tissues and/or attract T lymphocytes,
which bear selectivereceptors, namely, CCR4 (predomi-Figure 1. Schematic Model for Chemokine Receptors as Markers
for T Lymphocyte Differentiation nantly binds TARC), CCR6 (binds LARC), and CCR7
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(binds ELC) (Table 2). DC-CK1 is produced by dendritic Signal Transduction Pathways Activated
by Chemokines in T Lymphocytescells of germinal centers and T lymphocyte areas of
The biochemical events underlying the chemotactic ef-secondary lymphoid organs and is chemotactic for naive
fect as well as other biological roles of chemokines haveT lymphocytes, while TECK is produced by thymic den-
been a major focus of interest in many cell types fordritic cells and is chemotactic for macrophages, den-
several years, initially in the hope of discovering a worth-dritic cells, and thymocytes (Adema et al., 1997; Vicari
while therapeutic anti-inflammatory target. In this respect,et al., 1997). The restricted and constitutive production
however, the stakes have been raised considerablyof these chemokines in lymphoid tisues and/or their
given the diversity of biological outcomes increasinglyselective binding to chemokine receptors that are ex-
attributed to chemokines. One of the most extensivelypressed by T lymphocytes suggests that they may be
investigated chemokines with respect to signal trans-heavily involved in the regulation of lymphocyte traffick-
duction mechanisms in cells other than T lymphocytesing during development.
is the CC chemokine MCP-1. Several biochemical events
are stimulated by MCP-1, including inhibition of adenyl-
ate cyclase, activation of phospholipase C, calcium flux,Chemokine Receptors Act as Coreceptors for HIV-1
and inositol trisphosphate generation by G protein±An exciting and important advance in recent chemokine
dependent mechanisms (Baggiolini et al., 1997). Inresearch was the finding that certain CC chemokines
marked contrast, the signaling events initiated by chem-(e.g., RANTES,MIP-1a, and MIP-1b) can suppress infec-
okines in T lymphocytes are only now beginning to betion of T cells with the M-tropic HIV-1 strains (Cocchi
understood. In this respect, the best-characterizedet al., 1995). Several groups subsequently showed that
chemokines in terms of both their functional influenceCCR5 (the receptor for RANTES, MIP-1a, and MIP-1b),
on T lymphocytes and regulation of signal transductionis the coreceptor for M-tropic HIV-1. In contrast, CXCR4
mechanisms are the CC chemokine RANTES and theis the coreceptor responsible for the efficient entry of
CXC chemokine IL-8. As a result, these chemokinesT-tropic strains of HIV-1 into target cells. Accordingly,
serve as prototypes and reference points for studyingthe CXCR4 ligand SDF-1 blocks infection with T tropic,
signaling events elicited by other chemokines in T lym-but not M- or dual-tropic, HIV-1 (reviewed by Fauci,
phocytes.1996). At around the same time, homozygosity for a 32
Biochemical Signals activated by RANTESbp deletion in the human CCR5 gene (CCR5D32 allele),
RANTES is an extremely versatile chemokine in termswhich produces a mutant truncated protein that is not
of the functional T cell consequences that it has beenexpressed on the cell surface, was found to confer resis-
reported to influence. These range from control of uro-tance to infection by HIV-1 with no obvious deleterious
pod formation (a cytoplasmic projection indicative ofphenotype (Liu, et al., 1996; Samson et al., 1996). Sur-
cellular polarization) and expression of adhesion mole-prisingly, the D32 allele is quite common in individuals
cules during chemotaxis, to the regulation of cytokineof northern European descent. Another much rarer mu-
release and T cell proliferation as well as protectiontation, CCR5-m303 (which contains a premature stop
against HIV-1 (Figure 2). It is therefore critical to under-
codon at position 303), has also been reported to confer
stand whether these diverse functional outcomes are
resistance to HIV-1 infection (Quillent et al., 1998). Al-
controlled by discrete biochemical signaling cascades,
though CCR5 mutations clearly confer a very high level
since these may lead to the identification of a selective
of resistance to HIV infection, they are not infallible and therapeutic target.
it seems likely that there are other important resistance RANTES stimulates biphasic calcium mobilization in
factors. Indeed, later during the course of infection, T lymphocytes with the initial transient peak associated
T-tropic HIV-1 variants emerge that can also use CCR3, with chemotaxis. This initial transient calcium elevation
CCR2, and CCR5 in addition to CXCR4 (Connnor et is initiated by nanomolar concentrations and mediated
al., 1997). The emergence of these viruses has been by a heterotrimeric G protein±coupled pathway as evi-
suggested to coincide with a less favourable clinical denced by sensitivity to pertussis toxin. The second,
prognosis. Furthermore, a mutation (valine to isoleucine sustained peak of calcium influx is elicited by micromo-
switch at position 64) in the transmembrane region of lar concentrations of RANTES and is dependent on pro-
CCR2 also has a significant protective effect on HIV tein tyrosine kinases (PTKs), as evidenced by its sensi-
disease progression. The precise mechanism by which tivity to PTK inhibitors. This second peak of calcium
this CCR2±64I mutation influences protection against influx is associated with Ca21 channel opening, IL-2 re-
HIV-1 remains unclear, although it has been speculated ceptor expression, cytokine release, and T cell prolifera-
that it may be related to CCR5 heterozygosity, since tion (Bacon et al., 1995b). Interestingly, RANTES-induced
there is strong linkage disequilibrium between CCR2± calcium mobilization depends on the expression of CD3,
64I and a mutation (CCR5±59653T) in the regulatory re- but the full significance of this observation has yet to
gion of the closely linked CCR5 gene (Kostrikis et al., be demonstrated, although it may imply that RANTES
1998). It is also interesting to note that other CC chemo- may engage the TCR complex as a way of effecting
kines such as MDC (binds CCR4) can inhibit HIV-1 infec- cellular activation (Dairaghi et al., 1998). Given the partial
tion of T lymphocytes, while I-309 (binds CCR8) inhibits sensitivity of RANTES-stimulated calcium mobilization
CCR8-dependent infection of monocytes by diverse to PTK inhibitors, it is perhaps surprising that RANTES
HIV-1 strains, further suggesting that a number of che- stimulation has not been reported to induce tyrosine
mokine receptors are involved in HIV-1 entry (Pal et al., phosphorylation of phospholipase C, even though it in-
duces the tyrosine phosphorylation and activation of a1997; Horuk et al., 1998).
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Figure 2. Schematic Representation of the
Signaling Pathways Activated by RANTES in
T Lymphocytes
The mechanisms by which the RANTES re-
ceptor(s) couples to the PTKs are unclear
(represented by ª?º) and the diagram is not
meant to imply interaction of PTK(s) or G pro-
teins with any specific intracellular loop. Re-
ceptor engagement by RANTES stimulates
PTK activity, which results in the tyrosine
phosphorylation of the substrates indicated
(shown in green). Elevation of intracellular
calcium (shown in blue) is due in part to acti-
vation of a G protein±coupled PLC and open-
ing of a PTK-dependent calcium channnel.
RANTES also stimulates the p85/p110 heter-
odimeric form of PI3K (shown in red), al-
though it is unknown how the RANTES recep-
tor(s) couples to and activates PI3K in T
lymphocytes (denoted by ª?º). Given the
known coupling of the chemokine receptors
to G proteins, it is also possible that RANTES
may activate the G protein±coupled isoform
of PI3K, namely, PI3Kg. The RANTES recep-
tor couples to and activates Rho and PLD
(shown in purple) by unknown routes, al-
though G protein coupling and PI3K-depen-
dent routes are suggested. PTK-dependent
mechanisms may also operate by analogy
with other systems but are not indicated. The
effector targets downstream of PI3K, calcium
mobilization, PLD, p125FAK, and ZAP-70 fol-
lowing RANTES stimulation are unknown, al-
though several functional outcomes have
been attributed to RANTES as shown and
maybe differentially regulated by one ormore
of the depicted signaling cascades. Dotted
lines indicate putative pathways. See text for
further details and references.
number of other substrates including the PTKs ZAP-70, RANTES has also been demonstrated to stimulate
activation of a distinct phosphatidylinositol 3-kinasep125FAK, and the related Pyk-2 (Bacon et al., 1996; Davis
et al., 1997). Activation of these PTKs by RANTES gives (PI3K), namely, the p85/p110 heterodimeric PI3K. Cou-
pling of receptors to the p85/p110 heterodimeric PI3Kit the potential to interface with a number of downstream
biochemical events and so to potentially influence T cell is known to require interaction of SH2 domains within the
p85 regulatory subunit with specific phosphotyrosine-activation, gene transcription, cell cycle progression,
and even cell survival. Certainly, RANTES induces a containing binding motifs (Turner et al., 1995; Vanhaese-
broeck et al., 1997). Since no such recognized motifsfunctional molecular complex consisting of p125FAK,
ZAP-70, and the focal adhesion protein Paxillin, indicat- are present in known RANTES receptors, it is unclear
how the receptor couples to this PI3K, although othering that these molecules may be required for T cell focal
adhesions formed in response to RANTES stimulation G protein±coupled receptors such as fMLP receptors
are able to activate the p85/p110 heterodimeric PI3K(Bacon et al., 1996; Davis et al., 1997). RANTES also
stimulates the tyrosine phosphorylation and activation (Stephens et al., 1993; Kurosu et al., 1997). In light of
the demonstration that both PTK-dependent and G pro-of STAT1 and STAT3 that correlates with the induction
of gene expression of the STAT-inducible proto-onco- tein±dependent signaling events are triggered by RANTES
in T cells, it is interesting to note that the p85/p110 PI3Kgene c-fos in T cell lines (Wong and Fish, 1998). Both
MIP-1a and MIP-1b exhibit receptor specificity similar is synergistically activated by tyrosine-phosphorylated
peptides and bg subunits of G proteins (Kurosu et al.,to that observed to RANTES, and it is interesting to
note that tyrosine phosphorylation of Pyk-2, STAT1, and 1997). Given the well-established role for RANTES as a
chemotactic agent and evidence that RANTESpromotesSTAT3 are observed in response to these chemokines
(Davis et al., 1997; Wong and Fish, 1998). Although the T lymphocyte activation, it seems appropriate that
RANTES can activate a PI3K-dependent signaling cas-precise mechanisms involved remain obscure, RANTES
clearly stimulates PTK activation, and in this respect cade, since this cascade has been implicated in both
the regulation of chemotaxis and as a pivotal signalRANTES is similar to other G protein±coupled receptors
such as Bombesin and Vasopressin that can also couple involved in T cell activation (Wennstrom et al., 1994;
Ward et al., 1996). Indeed, RANTES-induced chemotaxisto PTKs (Zachary et al., 1991).
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and polarization of normal human T lymphocytes is in- Biochemical Signals Activated by IL-8
IL-8 is the best studied CXC chemokine with respect tohibited by pretreatment with the PI3K inhibitor wortman-
its activation of signal transuction events in T lym-nin (Turner et al., 1995).
phocytes. Several studies have indicated roles for phos-There are several outstanding questions relating to
phoinositide hydrolysis, protein kinase C activation, trans-the activation of PI3K by RANTES. First, the effect, if
membrane calcium flux, and PLD as signaling eventsany, of RANTES on the G protein±coupled form of PI3K
underlying T lymphocyte and NK cell responses to IL-8(referred to as PI3Kg) has yet to be elucidated. Certainly,
(Bacon et al., 1993, 1995a). Interestingly, IL-8 does notthere is evidence that both the p85/p110 heterodimer
stimulate PLD activation in neutrophils, suggesting thatand PI3Kg can be activated by a single receptor stimu-
IL-8 may discriminate between its cellular targets bylus, since stimulation of THP-1 cells with concanavo-
differentially engaging distinct signaling pathways inlin-A can activate both the p85/p110 heterodimer as well
neutrophils and T lymphocytes (Bacon et al., 1995a). Inas a distinct pertussis toxin±sensitive PI3K (Matsuo et
contrast to RANTES, the effects of IL-8 on PI3K activityal., 1996). It will therefore be important to assess the
in T lymphocytes remains unknown, although IL-8-stim-effect, if any, of chemokines such as RANTES on either
ulated migration of neutrophils is inhibited by the PI3KPI3Kg or other distinct PI3Ks such as the recently identi-
inhibitor wortmannin (Knall et al., 1997). Finally, IL-8fied PI3K-C2a or the PtdIns-specific 3-kinase (Van-
stimulation of mouse lymphocyte cell lines expressinghaesebroeck et al., 1997). Second, the possible ac-
CXCR1 results in activation of RhoA (Laudana et al.,tivation by RANTES of protein kinase B, a known
1997). It is an exciting prospect, therefore, that like thedownstream effector of both p85/p110- and PI3Kg-de-
CC chemokine RANTES, IL-8 may activate RhoA in nor-pendent signaling cascades, has yet to be reported.
mal T lymphocytes, although this has yet to be con-Finally, recent studies have revealed that RANTES also
firmed. Little is known about the signalingevents elicitedactivates phospholipase D (PLD) in Jurkat cells, and this
by other CXC chemokines, although MIG, IP-10, andactivation is dependent on the GTP-binding proteins
SDF can generally stimulate increases in intracellularARF and RhoA (Bacon et al., 1998). It is tempting to
calcium. In addition, the CXC chemokine SDF-1 inducesspeculate that PI3K may be involved in regulating RhoA
tyrosine phosphorylation of Pyk-2 (Davis et al., 1997).and hence PLD activation, since PI3K activity is known
At present, therefore, there is insufficient evidenceto be essential for receptor-mediated activation of the
available to indicate one way or the other as to whetherrelated GTPase Rac in mammalian cells, and the PI3K
distinct signaling cascades are preferentially activatedhomolog TOR2 controls Rho1 activation in Saccharo-
by CC or CXC chemokines. Nevertheless, theknowledgemyces cerevisiae (Hawkins et al., 1995; Schmidt et al.,
of chemokine signaling garnered from studies on RANTES1997). Rho has been implicated in regulating actin fila-
and IL-8 should provide useful points of reference forment organization and cell motility, so it is possible that
studying the signals activated by other chemokines.Rho plays an important role in mediating the chemotac-
tic effects of RANTES (Hall, 1998). PLD and the ARF
family of proteins have been implicated in the vesicle
What Is the Relevence of Chemokine Receptor
formation and retrograde transport of proteins between Signaling to HIV-1 Viral Entry?
Golgi and endoplasmic reticulum, and they may there-
Viral entry is a complex phenomenon in which glycopro-
fore operate a mechanism for receptor down-regulation
tein attachment to CD4 creates a high affinity binding
(Ktistakis et al., 1996). It is interesting to note, therefore, site for the chemokine coreceptor leading to membrane
that PI3K hasbeen shown tobe involved in growth factor fusion. The HIV envelope protein CD4 and the chemo-
receptor down-regulation and that agonist-stimulated kine coreceptor can form a heterotrimeric complex on
receptor internalization isa feature of severalchemokine the surface of cells, and the molecular mechanisms by
receptors including CCR5 (Joly et al., 1994; Aramori et which CXCR4, CCR3, and CCR5 facilitate internalization
al., 1997). However, little is currently known about the of HIV-1 are now beginning to be understood (Lapham
involvement of PI3K(s) in agonist-stimulated chemokine et al., 1996; Trkola et al., 1996; Wu et al., 1996). Using
receptor internalization. a panel of CCR5-CCR2B receptor chimeras, it has been
The signaling events elicited by RANTES that we have determined that regions of CCR5 involved in chemokine
just described are schematically depicted in Figure 2, ligand specificity and in the cofactor usage for various
along with several known functional effects of RANTES. HIV-1 strains are not identical. For instance, chemokine
To date there is insufficient evidence to attribute con- selectivity is mediated by the second extracellular loop,
trol of individual functional consequences to any one while cofactor usage is dependent on the NH2 terminus
signaling cascade. Nevertheless, RANTES-induced ho- and first extracellular loop (Rucker et al., 1996; Samson
motypic aggregation has been shown to be sensitive to et al., 1997). Consistent with this observation, antibodies
the tyrosine kinase inhibitor herbimycin A but resistant binding to the NH2-terminal region of CCR5 block HIV-1
to pertussis toxin, while lymphocyte uropod formation infection but have no effect on chemokine activity. How-
induced by chemokines can be completely inhibited by ever, one antibody that recognizes the second extracel-
pertussis toxin treatment (Del Pozo et al., 1996; Szabo lular loop of CCR5 blocks both the binding and the
et al., 1997). Hence, it is possible that the activation of biological activity of the ligands RANTES, MIP-1a, and
both G protein±dependent and PTK-dependent signal- MIP-1b as well as infection by M-tropic and dual-tropic
ing pathways by RANTES reflects differential regulation HIV-1 (Wu et al., 1997). Hence, whereas the specificity
of different functional events by these signaling cas- of CC chemokine binding to CCR5 is determined by a
single domain, the gp120-binding site is more complexcades.
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and probably involves at least two domains, although reticulum. A signal peptide fragment of gp160 binds
changes in the NH2 terminus can be sufficient to signifi- calmodulin, but the functional consequences of this in-
cantly disrupt gp120 binding and HIV entry. teraction has not been elucidated (Martoglioet al., 1997).
The significance of G protein±linked signaling to viral Furthermore, a recent study has indicated for the first
entry remains unclear, but there are at least two lines time that HIV-1 envelope proteins such as gp120 can
of evidence to indicate that chemokine signaling and induce the rapid, pertussis toxin±sensitive tyrosine phos-
HIV-1 entry are separable functions of CCR5. First, per- phorylation of the PTK Pyk-2 (Davis et al., 1997). Since
tussis toxin, genistein, and herbimycin A are all able to Pyk-2 can feed into both the MAP kinase and Jun kinase
inhibit RANTES signaling, but do not block the ability of signaling pathways and can modulate ion channel func-
RANTES to inhibit HIV-1 infection (Oravecz et al., 1996; tion, there may be a link between HIV-1 binding tochem-
Alkhatib et al., 1997). Second, truncation mutants of okine receptors and several signaling cascades known
CCR5 (which are unable to elicit intracellular calcium to regulate cell growth, cell survival, and cell differentia-
fluxes and chemotaxis in response to RANTES, MIP-1a, tion. In addition, a recent report has also demonstrated
and MIP-1b) or certain CCR5-CCR2 chimeras (which are that recombinant gp160 envelope proteins from M-tropic
lacking domains necessary to signal in response to their (but not T-tropic) HIV-1 can actually induce a calcium
natural chemokine ligands) are still able to function as signal through CCR5 on CD41 T cells and that envelope-
HIV-1 coreceptors (Atchison et al., 1996; Rucker et al., mediated signal transduction through CCR5 induces
1996; Farzan et al., 1997; Samson et al., 1997). However, chemotaxis of T cells (Weissman et al., 1997). Hence,
the involvement of pertussis-toxin-insensitive, G pro- although signal transduction through CCR5 may not
tein±linked signaling pathways in viral entry cannot be necessarily be required for efficient fusion and entry of
entirely ruled out. One possibility in this respect is that HIV-1, it is possible that this envelope protein±stim-
chemokines could inhibit viral entry by down-regulating ulated chemotactic response may contribute to the patho-
the expression of their receptors. Indeed, both CCR5 genesis of HIV in vivo by chemoattracting activated
and CXCR4 are endocytosed upon ligand binding. Al- CD41 cells to sites of viral replication and/or that CCR5
though the mechanisms of agonist-stimulated chemo- signaling may enhance viral replication by increasing
kine receptor internalization are not fully understood, the activation state of the target cells.
this event is also pertussis toxin insensitive (Oravecz
et al., 1996; Alkhatib et al., 1997; Amara et al., 1997).
However, it seems that internalization is not required for What Is the Relationship between T Cell Activation,
the coreceptor function of either CCR5 or CXCR4 for Chemokine Production, and Susceptibility
HIV-1 entry, since mutations of these receptors that to HIV-1 Infection?
prevent agonist-stimulated internalization do not impair CXC (e.g., IL-8), CC (e.g., RANTES, MIP-1a, and MIP-1b),
HIV-1 entry. In the case of both CXCR4 and CCR5, al- and C (e.g., lymphotactin) chemokines have all been
though HIV-1 entry was unaffected, the impairment of reported to be up-regulated after T cell activation. Com-
receptor internalization correlates with a decreased po- parison of the stimuli required for chemokine production
tency of their respective ligands as inhibitors of HIV-1
by T cells has shown that mitogenic stimulation elicits
infection (Alkhatib et al., 1997; Amara et al., 1997).
only small, temporal amounts of MIP-1a/b and RANTES,
Hence, it appears that the ability of a coreceptor to
whereas higher sustained amounts are elicited by CD3
internalize is not required for HIV-1 entry, although it
ligation (Wechsler et al., 1994; Riley et al., 1997). Undermay contribute to the HIV-1 suppressive effect of CXC
physiological conditions, commitment to optimal T celland CC chemokines, possibly by reducing the density
activation requires TCR/CD3 complex engagement inof coreceptors. In this respect, it is tempting tospeculate
combination with a costimulatory signal such as thatthat one or more PI3K isoforms may have some role to
provided by CD28 (Ward, 1996). Indeed, costimulationplay, given the recognized role of PI3K in mediating
of anti-CD3 MAb-stimulated T cellswith anti-CD28 MAb,growth factor receptor internalization and the ability of
results in a major augmentation of chemokines oversome chemokines to activate PI3K (Joly et al., 1994;
levels elicited by CD3 ligation alone, although other co-Turner et al., 1995). From our knowledge of the mecha-
stimulatory receptors such as CD2, CD4, or CD5 cannisms for activation of the p85/p110 heterodimeric PI3K
also costimulate the production of these chemokines,or PI3Kg, the lack of effect of PTK inhibitors and pertus-
albeit less effectively than CD28 (Riley et al., 1997). Fur-sis toxin on HIV-1 entry would appear to argue against
thermore, in genetically modified murine systems, fullthis possibility. Nevertheless, the growing diversity within
production of MIP-1a is dependent on CD28 costimula-both the PI3K family of enzymes and the functional con-
tion interactions and is controlled by pathways differentsequences known to require PI3K activation, together
from those regulating CD28-dependent Th1 and Th2with severe gaps in our knowledge regarding receptor
differentiation (Herold et al., 1997). However, in contrastregulation of certain classes of PI3K, suggests that this
to findings using human T cells, murine T cell productionpossibility merits further investigation.
of RANTES production appears to be constitutive andThere is growing evidence, however, to indicate that
independent of anti-CD3 and anti-CD28 costimulationHIV-1 envelope glycoproteins may be more versatile
(Herold et al., 1997; Riley et al., 1997). Hence, the reg-with respect to their interaction with signaling pathways
ulation of RANTES production may differ between hu-than anticipated up tonow. For instance, the HIV-1 enve-
man and murine cells. Interestingly, IL-2 cannot inducelope protein gp160, like secretory proteins and most
chemokine production, even though it can induce T cellmembrane proteins, is synthesized with a signal se-
expression of several chemokine receptors such asquence that is usually cleaved from the nacent polypep-
tide during transport into the lumen of the endoplasmic CCR1 and CCR2. However, stimulation of these T cells
Immunity
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with anti-CD3 and anti-CD28 Abs reduced CCR1 and required for receptor regulation of the RANTES promoter
have not so far been investigated, but this is an intriguingCCR2 expression (Loetscher et al., 1996b; Herold et al.,
1997). Thus, T cell production of chemokines and their area that will hopefully be addressed in the very near
future.responses to secreted chemokines appear to be regu-
lated by the costimulatory signals that are available. If
CD28 is ligated, T cells produce chemokines as well as
Regulation of CCR5 Expression by CD28cytokines such as IL-2, but as a consequence they lose
Contributes to HIV-1 Resistanceresponsiveness to chemotactic molecules. It might be
Although other accessory molecules such as CD2, CD4,predicted, therefore, that cells specific for the presented
and CD5 can produce levels of CC chemokines similarantigen will remain at the site of antigen and will recruit
to those produced by CD28 ligation, the induction ofother cells that have not yet encountered antigen to that
HIV-1 resistance is specific to CD28, suggesting thatlocation, thus serving to ultimately amplify the immune
CD28 can exert an additional effect(s) (Riley et al., 1997).response.
Indeed, CD3/CD28 stimulation induces an HIV-1-resis-In view of the fact that HIV-1 infection of T lympho-
tant T cell phenotype characterized by a lack of expres-cytes is critically influenced by CC chemokines, and
sion of the CCR5 HIV-1 receptor. In contrast, levels ofbecause several chemokines are strongly up-regulated
CXCR4 are abundant in CD28 costimulated T cells, whileupon CD28 ligation, the effect of CD28 ligation on HIV-1
PHA-activated cells express both CCR5 and CXCR4infection of T cells was investigated. Indeed, activation
(Carroll et al., 1997). These effects of CD28 ligation onof CD28 with immobilized anti-CD28 Abs or with its
CCR5 and CXCR4 expression are consistent with thenatural ligand B7.1 in combination with anti-CD3 Abs
observation that only the M-tropic viruses are suscepti-induces a potent anti-HIV-1 effect. These stimuli can
ble to the CD28 antiviral effect, whereas CD28-costimu-still promote the long-term polyclonal proliferation of
lated cells are sensitive to the T-tropic virus. Further-T cells from HIV-1-infected donors in the absence of
more, CD4 expression and the binding of HIV-1 gp120exogenous cytokines or feeder cells. The CD28-depen-
to CD28-stimulated cells are normal, and the antiviraldent anti-viral effect acted early in the viral life cycle.
effect appears to be blocked at the level of membraneThis effect is, however, due only in part to the enhanced
fusion. Overall, it appears that CD28 costimulation inproduction of the CC chemokines RANTES, MIP-1a, and
vitro induces a form of cellular resistance to HIV-1 infec-MIP-1b, which block infection by M-tropic isolates via
tion independent of the effects of CD28 on T cell prolifer-CCR5 (Levine et al., 1996; Riley et al., 1997). The mecha-
ation, and this resistance is similar to that recently de-nisms by which CD28 protects against HIV-1 infection
scribed in individuals with a genetic disruption of thealso involve regulation of CCR5 expression, as dis-
CCR5 gene (Liu et al., 1996; Samson et al., 1996). Thecussed further in the next section. The resistance of
identification of the CD28-dependent regulation of CCanti-CD3 and anti-CD28 costimulated T cells to some
chemokines and CCR5 may therefore have importantstrains of HIV-1 in vitro is somewhat paradoxical, how-
therapeutic implications both for preventing infectionever, since it is well established that antigen presenta-
and for limiting viral spread in patients with HIV-1 infec-tion in vivo leads to increased viral replication, indicating
tion. The CD28 homolog CTLA-4 plays a critical inhibi-that viral presentation in vivo is much more complex
tory role during T cell activation, but there are no reportsand dependent on many other cellular events.
concerning the effects of CTLA-4 on CC chemokine pro-Up-regulation of chemokine production following T
duction or chemokine receptor regulation; one mightlymphocyte activation is poorly understood, but is
predict that CTLA-4 may promote HIV-1 infection by up-likely to involve effects on transcriptional mechanisms.
regulating CCR5 expression (Chambers et al., 1996). TheRANTES is the best-studied CC chemokine in terms of
outcome of CTLA-4 on CCR5 expression is thereforetranscriptional regulation of chemokines in T cells and
eagerly awaited.is up-regulated late (3±5 days) after PHA activation in
normal T lymphocytes. In contrast, RANTES mRNA is
up-regulated quickly (24±48 hr) by TNF-a in fibroblasts,
Chemokines as Therapy for HIVrenal epithelial and mesangial cells, and smooth muscle
Several modified chemokine derivatives that act as re-cells (Ortiz et al., 1997). The RANTES promoter contains
ceptor antagonists and do not induce chemotaxis haveseveral important regions (termed A±E) that can bind
been shown to inhibit M-tropic strains of HIV-1 includingnovel transcription factors and that identify both early
the NH2-terminal truncated RANTES (9±68), Met-RANTESand late-acting transcriptional regulatory pathways con-
(which has a single extra methionine residue at the NH2tributing to RANTES gene expression. The RANTES pro-
terminus), and aminooxypentane (AOP)-RANTES (whichmoter also contains four NF-kB binding sites, one of
has chemically added hydrocarbons at the NH2 termi-which serves as a CD28-responsive element (CD28RE)
nus) (Arenzana-Seisdedos et al., 1996; Simmons et al.,similar to that decribed in the IL-2 promoter (Ortiz et al.,
1997). There are, however, several drawbacks to using1997). Interestingly, a CD28RE has also been identified
chemokine antagonists, since their use could be gener-in the IL-8 promoter. Indeed, stimulation with anti-CD3
ally immunosuppressive. Most recently, three unrelatedMAb alone is able to induce RANTES and IL-8 promoter
small molecular weight compounds, previously knownactivity, while costimulation with anti-CD3 and anti-
for their inhibitory effects on HIV-1 replication, haveCD28 Ab further increased the activity. Moreover, muta-
been shown to block entry of T- but not M-tropic strainstion of the CD28RE prevented RANTES promoter activity
by interacting with CXCR4, probably by competition forinduced by CD28 ligation (Moriuchi et al., 1997; Wech-
sler et al., 1994). The biochemical signaling cascades coreceptor binding by the virus (Baggiolini and Moser,
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receptor CCR5: receptor signaling and internalization are dissocia-1997). In addition, a viral chemokine-like protein, vMIP-
ble from its role as an HIV-1 co-receptor. EMBO J. 16, 4606±4616.II, may serve as a tantalizing lead compound for the
Arenzana-Seisdedos, F., Virelizier, J-L., Rousset, D., Clark-Lewis,development of broad spectrum anti-HIV agents. This
I., Loetscher, P., Moser, B. and Baggiolini, M. (1996). HIV blockedprotein blocks calcium mobilization and chemotaxis in-
by chemokine antagonist. Nature 383, 400.
duced by several other chemokines as well as entry of
Atchison, R.E., Gosling, J., Monteclaro, F.S., Franci, C., Digilio, L.,
HIV-1 mediated through CCR3, CCR5, or CXCR4 (Kle- Charo, I.F., and Goldsmith, M.A. (1996). Multiple extracellular ele-
dal et al., 1997). Finally, genetically modified CC (e.g., ments of CCR5 and HIV-1 entry: dissociation from response to
RANTES and MIP-1a) and CXC (e.g., SDF-1)chemokines chemokine. Science 274, 1924±1926.
have been targeted to the endoplasmic reticulum lumen Bacon, K.B., Quinn, D.G., Aubry, J.P. and Camp, R.D. (1993). In-
terleukin-8-stimulated polyphosphoinositide hydrolysis in humanto intracellularly bind the newly synthesized CCR5 or
peripheral blood lymphocytes. Blood 81, 430±436.CXCR4, respectively, and which consequently prevents
Bacon, K.B., Flores-Romo, L., Life, P.F., Taub, D.D., Premack, B.A.,their transport to the cell surface. The T lymphocytes
Arkinstall, S.J., Wells, T.N.C., Schall, T.J., and Power, C.A. (1995a).expressing these ªintrakinesº were subsequently found
IL-8-induced signal transduction in T lymphocytes involves recep-
to resist M- and T-tropic HIV-1 infection (Chen et al., tor-mediated activation of phospholipases C and D. J. Immunol.
1997; Yang et al., 1997). This gene-based intrakine 154, 3654±3666.
therapy using genetically modified lymphocytes may Bacon, K.B., Premack, B.A., Gardner, P., and Schall, T.J. (1995b).
have a potent and longer-lasting anti-HIV-1 action than Activation of dual T cell signaling pathways by the chemokine
RANTES. Science 269, 1727±1729.that achieved by the adminstration of chemokines that
Bacon, K.B., Szabo, M.C., Yssel, H., Bolen, J., and Schall, T.J. (1996).have a short half-life in vivo.
RANTES induces tyrosine kinase activity of stably complexedIn just a few years, there has been an explosion of
p125FAK and ZAP-70 in human T cells. J. Exp. Med. 184, 873±882.interest and understanding of what chemokines are and
Bacon, K.B., Schall, T.J., and Dairaghi, D. (1998). RANTES activationwhat they do in a number of functional settings, and it
of phospholipase D in Jurkat T cells: requirement of GTP-binding
is now clear that their role in T lymphocyte biology is proteins ARF and RhoA. J. Immunol. 160, 1894±1900.
not restricted just to cell attraction. In contrast, progress
Baggiolini, M., and Moser, B. (1997). Blocking chemokine receptors.
in understanding the biochemical events underlying J. Exp. Med. 186, 1189±1191.
chemokine receptor ligation in T cells has been much Baggiolini, M., Dewald, B., and Moser, B. (1997). Human chemo-
slower, although an interesting and rather complex pic- kines. Annu. Rev. Immunol. 15, 675±705.
ture of chemokine receptor signaling machinary is now Bleul, C.C., Wu, L., Hoxie, J.A., Springer, T.A., and MacKay, C.R.
beginning to emerge. The generation and use of trans- (1997). The HIV co-receptors CXCR4 and CCR5 are differentially
expressed and regulated on human T lympocytes. Proc. Natl. Acad.genic and knockout mice models of chemokines and/or
Sci. USA 94, 1925±1930.chemokine receptor(s) should ultimately prove essential
Bonecchi, R., Bianchi, G., Bordignon, P.P., D'Ambrosio, D., Lang,tools in plugging the gaps in our knowledge regarding
R., Borsatti, A., Sozzani, S., Allavena, P., Gray, P.A., Mantovani,precise functional importance of individual chemokines.
A., and Sinigaglia, F. (1998). Differential expression of chemokine
However, we are some way from being able to attribute receptors and chemotactic responsiveness of type 1 T helper cells
functional consequences to discrete pathways, which (Th1s and Th2s). J. Exp. Med. 187, 129±134.
would be beneficial in identifying future specific thera- Carroll, R.G., Riley, J.L., Levine, B.L., Feng, Y., Kaushal, S., Ritchey,
peutic drug targets. One can only hope that as the dis- D.W., Bernstein, W., Weislow, O.S., Brown, C.R., Berger, E.A., et al.
(1997). Differential regulation of HIV-1 fusion cofactor expressioncovery of more chemokines and their receptors continues
by CD28 costimulation of CD41 T cells. Science 276, 273±276.unabated, understanding of their functional relevence
Chambers., C.A., Krummel, M.F., Boitel, B., Hurwitz, A., Sullivan,and chemokine receptor signal transduction mecha-
T.J., Fournier, S., Cassell, D., Brunner, M., and Allison, J.P. (1996).nisms continues to progress at a comparable rate. The role of CTLA-4 in the regulation and initiation of T cell responses.
Immunol. Rev. 153, 27±46.
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